MAM
CSTL icon

Martingale Asset Management’s Castle Biosciences CSTL Stock Holding History

Martingale Asset Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-13,555
Closed -$902K – 835
2021
Q3 		$902K Buy
13,555
+8,250
+156% +$581K 0.01% 533
2021
Q2 		$390K Sell
5,305
-100
-2% -$6.61K ﹤0.01% 665
2021
Q1 		$371K Sell
5,405
-100
-2% -$7.52K ﹤0.01% 694
2020
Q4 		$370K Sell
5,505
-21,500
-80% -$1.17M ﹤0.01% 699
2020
Q3 		$1.39M Buy
+27,005
New +$1.2M 0.02% 527

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Martingale Asset Management's CSTL Position: Q4 2021 in Review

Martingale Asset Management sold out of Castle Biosciences (CSTL) in Q4 2021, closing a stake of 13,555 shares — an estimated $902K sold.

Martingale Asset Management first reported a position in CSTL in Q3 2020 and held it in 5 quarters. The position peaked at $1.39M in Q3 2020. 159 funds tracked by Wall St. Rank hold CSTL as of Q4 2021.

  • Martingale Asset Management reported no remaining Castle Biosciences position as of Q4 2021 after selling out during the quarter.
  • Martingale Asset Management sold 13,555 Castle Biosciences shares in Q4 2021, an estimated $902K.
  • Martingale Asset Management first reported a position in Castle Biosciences in Q3 2020 and held it in 5 quarters.
  • Martingale Asset Management's Castle Biosciences position peaked at $1.39M in Q3 2020.
  • 159 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2021.

Based on Martingale Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.